Toujeo

Active Ingredient(s): Insulin Glargine
FDA Approved: * February 25, 2015
Pharm Company: * SANOFI AVENTIS US
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Toujeo Overview

Insulin glargine, marketed under the names Lantus among others, is a long-acting insulin, used in the management of type I and type II diabetes.[1] It is not typically the recommended long acting insulin in the United Kingdom.[2] It is used once a day as an injection just under the skin.[1] Effects generally begin an hour after use.[1] Common side effects include low blood sugar, problems at the site of injection, itchiness, and ...

Read more Toujeo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Insulin_glargine

Recent Toujeo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Insulin Glargine

Injection: 100 Units/ml, 100unit/ml, 300 Units/ml
Solution: 300 Units/3ml (100 Units/ml), 300 Units/ml (300 Units/ml), 300units/ml (300units/ml), 450 Units/1.5ml (300 Units/ml), 900 Units/3ml (300 Units/ml)

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Toujeo: (2 results)

Sorted by National Drug Code

0024-5869 Toujeo 300 U/Ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
50090-2193 Toujeo 300 U/Ml Subcutaneous Injection, Solution by A-s Medication Solutions

Other drugs which contain Insulin Glargine or a similar ingredient: (4 results)

BASAGLAR Insulin Glargine1 discussion
INSULIN GLARGINE
INSULIN GLARGINE + LIXISENATIDE
SOLIQUA Insulin Glargine + Lixisenatide